NYXOAH SA (NYXH) Stock Fundamental Analysis

NASDAQ:NYXH • BE0974358906

4.49 USD
+0.06 (+1.35%)
Last: Feb 17, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

NYXH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. NYXH has a bad profitability rating. Also its financial health evaluation is rather negative. NYXH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • NYXH had negative earnings in the past year.
  • NYXH had a negative operating cash flow in the past year.
  • NYXH had negative earnings in each of the past 5 years.
  • NYXH had a negative operating cash flow in each of the past 5 years.
NYXH Yearly Net Income VS EBIT VS OCF VS FCFNYXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • NYXH's Return On Assets of -89.29% is on the low side compared to the rest of the industry. NYXH is outperformed by 76.76% of its industry peers.
  • With a Return On Equity value of -164.01%, NYXH is not doing good in the industry: 69.19% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -89.29%
ROE -164.01%
ROIC N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
NYXH Yearly ROA, ROE, ROICNYXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • The Gross Margin of NYXH (64.36%) is better than 67.57% of its industry peers.
  • In the last couple of years the Gross Margin of NYXH has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
NYXH Yearly Profit, Operating, Gross MarginsNYXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NYXH has more shares outstanding
  • NYXH has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, NYXH has a worse debt to assets ratio.
NYXH Yearly Shares OutstandingNYXH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NYXH Yearly Total Debt VS Total AssetsNYXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -4.39, we must say that NYXH is in the distress zone and has some risk of bankruptcy.
  • NYXH's Altman-Z score of -4.39 is on the low side compared to the rest of the industry. NYXH is outperformed by 65.95% of its industry peers.
  • A Debt/Equity ratio of 0.40 indicates that NYXH is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.40, NYXH perfoms like the industry average, outperforming 47.03% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z -4.39
ROIC/WACCN/A
WACC7.48%
NYXH Yearly LT Debt VS Equity VS FCFNYXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • NYXH has a Current Ratio of 1.70. This is a normal value and indicates that NYXH is financially healthy and should not expect problems in meeting its short term obligations.
  • NYXH has a Current ratio of 1.70. This is in the lower half of the industry: NYXH underperforms 69.73% of its industry peers.
  • A Quick Ratio of 1.41 indicates that NYXH should not have too much problems paying its short term obligations.
  • NYXH's Quick ratio of 1.41 is in line compared to the rest of the industry. NYXH outperforms 41.08% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.41
NYXH Yearly Current Assets VS Current LiabilitesNYXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The earnings per share for NYXH have decreased strongly by -30.42% in the last year.
  • NYXH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.96%.
  • The Revenue has been growing by 74.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.02%
Revenue 1Y (TTM)10.96%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%55.77%

3.2 Future

  • Based on estimates for the next years, NYXH will show a small growth in Earnings Per Share. The EPS will grow by 2.61% on average per year.
  • Based on estimates for the next years, NYXH will show a very strong growth in Revenue. The Revenue will grow by 117.81% on average per year.
EPS Next Y-21.84%
EPS Next 2Y-9.03%
EPS Next 3Y2.61%
EPS Next 5YN/A
Revenue Next Year48.25%
Revenue Next 2Y136.46%
Revenue Next 3Y138.58%
Revenue Next 5Y117.81%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NYXH Yearly Revenue VS EstimatesNYXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
NYXH Yearly EPS VS EstimatesNYXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NYXH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYXH Price Earnings VS Forward Price EarningsNYXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYXH Per share dataNYXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.03%
EPS Next 3Y2.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NYXH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NYXOAH SA

NASDAQ:NYXH (2/17/2026, 8:00:02 PM)

4.49

+0.06 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-19
Inst Owners17.27%
Inst Owner Change12.64%
Ins Owners19.98%
Ins Owner ChangeN/A
Market Cap193.20M
Revenue(TTM)5.64M
Net Income(TTM)-83.57M
Analysts81.43
Price Target11.31 (151.89%)
Short Float %1.08%
Short Ratio7.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.07%
Min EPS beat(2)-5.02%
Max EPS beat(2)5.16%
EPS beat(4)2
Avg EPS beat(4)-4.98%
Min EPS beat(4)-22.16%
Max EPS beat(4)5.16%
EPS beat(8)5
Avg EPS beat(8)-2.41%
EPS beat(12)6
Avg EPS beat(12)-9.44%
EPS beat(16)9
Avg EPS beat(16)-3.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.35%
Min Revenue beat(2)-1.4%
Max Revenue beat(2)-1.3%
Revenue beat(4)0
Avg Revenue beat(4)-19.45%
Min Revenue beat(4)-38.43%
Max Revenue beat(4)-1.3%
Revenue beat(8)1
Avg Revenue beat(8)-18.47%
Revenue beat(12)1
Avg Revenue beat(12)-25.3%
Revenue beat(16)1
Avg Revenue beat(16)-32.33%
PT rev (1m)0.81%
PT rev (3m)-19.82%
EPS NQ rev (1m)-1.87%
EPS NQ rev (3m)-1.46%
EPS NY rev (1m)0.4%
EPS NY rev (3m)2.4%
Revenue NQ rev (1m)32.07%
Revenue NQ rev (3m)17.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28.97
P/FCF N/A
P/OCF N/A
P/B 3.21
P/tB 193.11
EV/EBITDA N/A
EPS(TTM)-2.65
EYN/A
EPS(NY)-2.53
Fwd EYN/A
FCF(TTM)-1.9
FCFYN/A
OCF(TTM)-1.86
OCFYN/A
SpS0.15
BVpS1.4
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -89.29%
ROE -164.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.36%
FCFM N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.99%
Cap/Sales 21.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.7
Quick Ratio 1.41
Altman-Z -4.39
F-Score3
WACC7.48%
ROIC/WACCN/A
Cap/Depr(3y)64.88%
Cap/Depr(5y)74.74%
Cap/Sales(3y)37.33%
Cap/Sales(5y)219.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.02%
EPS Next Y-21.84%
EPS Next 2Y-9.03%
EPS Next 3Y2.61%
EPS Next 5YN/A
Revenue 1Y (TTM)10.96%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%55.77%
Revenue Next Year48.25%
Revenue Next 2Y136.46%
Revenue Next 3Y138.58%
Revenue Next 5Y117.81%
EBIT growth 1Y-59.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-47.24%
EBIT Next 3Y-14.81%
EBIT Next 5Y11.04%
FCF growth 1Y-49.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.83%
OCF growth 3YN/A
OCF growth 5YN/A

NYXOAH SA / NYXH FAQ

What is the fundamental rating for NYXH stock?

ChartMill assigns a fundamental rating of 2 / 10 to NYXH.


Can you provide the valuation status for NYXOAH SA?

ChartMill assigns a valuation rating of 0 / 10 to NYXOAH SA (NYXH). This can be considered as Overvalued.


Can you provide the profitability details for NYXOAH SA?

NYXOAH SA (NYXH) has a profitability rating of 1 / 10.


What is the financial health of NYXOAH SA (NYXH) stock?

The financial health rating of NYXOAH SA (NYXH) is 2 / 10.


Can you provide the expected EPS growth for NYXH stock?

The Earnings per Share (EPS) of NYXOAH SA (NYXH) is expected to decline by -21.84% in the next year.